Compare USNA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | LCTX |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.0M | 391.1M |
| IPO Year | 1996 | 1996 |
| Metric | USNA | LCTX |
|---|---|---|
| Price | $19.06 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 109.5K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $1,060,902,000.00 | $14,556,000.00 |
| Revenue This Year | $3.90 | $109.40 |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $32.59 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $16.60 | $0.40 |
| 52 Week High | $38.32 | $2.09 |
| Indicator | USNA | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 54.06 |
| Support Level | $18.67 | $1.56 |
| Resistance Level | $21.35 | $1.82 |
| Average True Range (ATR) | 0.56 | 0.08 |
| MACD | 0.29 | 0.02 |
| Stochastic Oscillator | 98.19 | 74.47 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.